Explore the benefits of the Precision GLP-1 agonist, a new therapy that improves glycaemic control and reduces side effects.

BERLIN — A novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist combined into a single drug (LY3298176, Lilly), dubbed a "twincretin," ...

Significantly less progression, especially unstable lesions, with relugolix versus leuprol ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — New recommendations from ACP on type 2 diabetes treatment include adding a GLP-1 agonist or SGLT-2 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. GLP-1 agonists and co-agonists conferred better ...

Among patients with type 2 diabetes, glucagon-like peptide 1 (GLP-1) receptor agonists reduced their risk of obesity-related cancers more than insulin did. Use of the drug class was also linked to a ...

About The Study: Glucagon-like peptide receptor agonists (GLP-1RAs) were associated with lower risks of specific types of obesity-associated cancers compared with insulins or metformin in patients ...

The interplay between host immunity, the microbiota, and cancer is a rapidly evolving area of immuno-oncology. An increasing body of evidence highlights the ...